Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

RXRX Company Profile and Key Details

NASDAQ : RXRX

Recursion Pharmaceuticals, Inc.

$10.64
0.11+1.04%
At Close 4:00 PM
$10.45
-0.19-1.79%
After-Market 05:18 PM
73.23
BESG ScoreESG Rating

RXRX Stock Price Chart

Stock Price Today

Recursion Pharmaceuticals, Inc. (RXRX) stock surged +1.04%, trading at $10.64 on NASDAQ, up from the previous close of $10.53. The stock opened at $11.55, fluctuating between $10.42 and $12.36 in the recent session.

Stock Snapshot

10.53
Prev. Close
11.55
Open
4.08B
Market Cap
383.72M
Number of Shares
10.415
Day Low
12.36
Day High
-6.91
P/E Ratio
84.17%
Free Float in %
-1.54
EPS (TTM)
1.99
Book Value
-1.29
Cash Flow per Share
70.81M
Volume

Stock Price History Chart

DateOpenHighLowCloseVolume
Feb 18, 202511.5412.3610.4210.6470.93M
Feb 14, 20259.1510.759.0410.5381.43M
Feb 13, 20258.268.517.948.5028.42M
Feb 12, 20257.438.397.388.3434.83M
Feb 11, 20257.487.917.337.6623.72M
Feb 10, 20257.698.107.487.6526.03M
Feb 07, 20257.357.887.227.4924.63M
Feb 06, 20258.148.287.157.2455.59M
Feb 05, 20257.708.237.607.9226.75M
Feb 04, 20257.417.777.317.6115.44M
Feb 03, 20256.947.366.897.2515.57M
Jan 31, 20257.917.967.157.2421.32M
Jan 30, 20257.387.897.257.6917.15M
Jan 29, 20257.427.756.957.1612.96M
Jan 28, 20257.077.496.897.4313.23M
Jan 27, 20256.987.336.727.0321.35M
Jan 24, 20257.648.267.267.3325.17M
Jan 23, 20257.247.727.147.5316.55M
Jan 22, 20257.178.057.177.4936.47M
Jan 21, 20256.747.176.666.8813.7M

Contact Details

Salt Lake City, UT 84101

United States

Website: https://www.recursion.comContact: 385 269 0203

About Company

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Company Information

Employees500
Beta0.86
Sales or Revenue$44.58M
5Y Sales Change%19.78%
Fiscal Year EndsDecember
SectorHealthcare
IndustryBiotechnology

Frequently Asked Questions

What is the current Recursion Pharmaceuticals, Inc. (RXRX) stock price?

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) stock price is $10.64 in the last trading session. During the trading session, RXRX stock reached the peak price of $12.36 while $10.42 was the lowest point it dropped to. The percentage change in RXRX stock occurred in the recent session was 1.04% while the dollar amount for the price change in RXRX stock was $0.11.

RXRX's industry and sector of operation?

The NASDAQ listed RXRX is part of Biotechnology industry that operates in the broader Healthcare sector. Recursion Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of RXRX?

Mr. Ryan Kelly
Managing Director
Dr. Michael Secora Ph.D.
Chief Financial Officer
Ms. Tina Marriott Larson
Chief Operating Officer & Pres
Ms. Louisa Daniels J.D., M.B.A.
Chief Legal Officer & Gen. Counsel
Kevin Leggat
Vice President of Fin. & Accounting
Dr. Blake C. Borgeson Ph.D.
Co-Founder & Director
Dr. Christopher C. Gibson Ph.D.
Co-Founder, Chief Executive Officer & Director
Mr. Benjamin Mabey M.S.
Chief Technology Officer
Dr. Shafique Virani M.D.
Chief Corporation Devel. Officer
Mr. Jared Allenbach
Senior Director of Investor Relations
Ms. Heather Kirkby M.B.A.
Chief People Officer

How RXRX did perform over past 52-week?

RXRX's closing price is 90% higher than its 52-week low of $5.60 where as its distance from 52-week high of $15.74 is -32.4%.

How many employees does RXRX have?

Number of RXRX employees currently stands at 500.

Link for RXRX official website?

Official Website of RXRX is: https://www.recursion.com

How do I contact RXRX?

RXRX could be contacted at phone 385 269 0203 and can also be accessed through its website. RXRX operates from 41 South Rio Grande Street, Salt Lake City, UT 84101, United States.

How many shares of RXRX are traded daily?

RXRX stock volume for the day was 70.81M shares. The average number of RXRX shares traded daily for last 3 months was 19.3M.

What is the market cap of RXRX currently?

The market value of RXRX currently stands at $4.08B with its latest stock price at $10.64 and 383.72M of its shares outstanding.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph